<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><!--The publisher of this article does not allow downloading of the full text in XML form.--><front><journal-meta><journal-id journal-id-type="nlm-ta">Drug Alcohol Depend</journal-id><journal-id journal-id-type="iso-abbrev">Drug Alcohol Depend</journal-id><journal-id journal-id-type="pmc-domain-id">319</journal-id><journal-id journal-id-type="pmc-domain">nihpa</journal-id><journal-title-group><journal-title>Drug and alcohol dependence</journal-title></journal-title-group><issn pub-type="ppub">0376-8716</issn><issn pub-type="epub">1879-0046</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>NIHPA Author Manuscripts</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC9777057</article-id><article-id pub-id-type="pmcid-ver">PMC9777057.1</article-id><article-id pub-id-type="pmcaid">9777057</article-id><article-id pub-id-type="pmcaiid">9777057</article-id><article-id pub-id-type="manuscript-id">NIHMS1852217</article-id><article-id pub-id-type="pmid">36423462</article-id><article-id pub-id-type="doi">10.1016/j.drugalcdep.2022.109707</article-id><article-id pub-id-type="manuscript-id-alternative">NIHMS1852217</article-id><article-id pub-id-type="manuscript-id-alternative">NIHPA1852217</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Article</subject></subj-group></article-categories><title-group><article-title>The impact of benzodiazepine exposure on treatment retention in an open-access methadone program: A retrospective cohort study</article-title></title-group><contrib-group><contrib contrib-type="author"><name name-style="western"><surname>Morford</surname><given-names initials="KL">Kenneth L.</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Tetrault</surname><given-names initials="JM">Jeanette M.</given-names></name><degrees>MD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Zhou</surname><given-names initials="B">Bin</given-names></name><degrees>MS</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Li</surname><given-names initials="F">Fangyong</given-names></name><degrees>MPH, MS</degrees><xref rid="A5" ref-type="aff">5</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gleeson</surname><given-names initials="B">Brynna</given-names></name><degrees>BA</degrees><xref rid="A4" ref-type="aff">4</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Edelman</surname><given-names initials="EJ">E. Jennifer</given-names></name><degrees>MD, MHS</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A2" ref-type="aff">2</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Stein</surname><given-names initials="MD">Michael D.</given-names></name><degrees>MD</degrees><xref rid="A6" ref-type="aff">6</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Barry</surname><given-names initials="DT">Declan T.</given-names></name><degrees>PhD</degrees><xref rid="A1" ref-type="aff">1</xref><xref rid="A3" ref-type="aff">3</xref><xref rid="A7" ref-type="aff">7</xref></contrib><contrib contrib-type="author"><name name-style="western"><surname>Madden</surname><given-names initials="L">Lynn</given-names></name><degrees>PhD, MPA</degrees><xref rid="A2" ref-type="aff">2</xref><xref rid="A3" ref-type="aff">3</xref></contrib></contrib-group><aff id="A1"><label>1</label>Program in Addiction Medicine, Yale School of Medicine, 367 Cedar Street, Suite 417A, New Haven, CT 06510, United States.</aff><aff id="A2"><label>2</label>Department of Internal Medicine, Yale School of Medicine, 333 Cedar Street, P.O. Box 208056, New Haven, CT 06510, United States.</aff><aff id="A3"><label>3</label>APT Foundation, 1 Long Wharf Drive, New Haven, CT 06511, United States.</aff><aff id="A4"><label>4</label>Vassar College, 124 Raymond Avenue, Poughkeepsie, NY 12604, United States.</aff><aff id="A5"><label>5</label>Yale Center for Analytic Sciences, Yale School of Public Health, P.O. Box 208034, New Haven, CT 06520, United States.</aff><aff id="A6"><label>6</label>Department of Health Law, Policy and Management, Boston University School of Public Health, 715 Albany St, Boston, MA 02118. United States.</aff><aff id="A7"><label>7</label>Department of Psychiatry, Yale School of Medicine, 300 George Street, Suite 901, New Haven, CT 06511, United States.</aff><author-notes><fn fn-type="con" id="FN1"><p id="P1">Contributors</p><p id="P2">All authors materially participated in the research and/or manuscript preparation and approved the final article.</p><p id="P3">Concept and design: Morford, Tetrault</p><p id="P4">Acquisition, analysis, or interpretation of data: Zhou, Li, Gleeson, Morford</p><p id="P5">Drafting of manuscript: Morford</p><p id="P6">Critical revision of the manuscript for important intellectual content: All authors</p><p id="P7">Administrative, technical, or material support: Barry, Madden, Morford</p><p id="P8">Supervision: Madden, Tetrault, Stein</p></fn><corresp id="CR1"><bold>Corresponding author:</bold> Kenneth L. Morford, MD, Yale School of Medicine, 367 Cedar Street, ESH 305A, New Haven, CT 06510, United States, phone 475-355-4826 fax 203-737-3306, <email>kenneth.morford@yale.edu</email></corresp><fn fn-type="COI-statement" id="FN2"><p id="P37">Conflict of interest</p><p id="P38">All authors have no declarations or conflicts of interest to report.</p></fn></author-notes><pub-date pub-type="ppub"><day>01</day><month>12</month><year>2022</year></pub-date><pub-date pub-type="epub"><day>19</day><month>11</month><year>2022</year></pub-date><volume>241</volume><issue-id pub-id-type="pmc-issue-id">424208</issue-id><fpage>109707</fpage><lpage>109707</lpage><pub-history><event event-type="nihms-submitted"><date><day>08</day><month>12</month><year>2022</year></date></event><event event-type="pmc-release"><date><day>01</day><month>12</month><year>2023</year></date></event><event event-type="pmc-live"><date><day>01</day><month>12</month><year>2023</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2024-06-13 18:25:21.900"><day>13</day><month>06</month><year>2024</year></date></event></pub-history><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="nihms-1852217.pdf"/><abstract id="ABS1"><sec id="S1"><title>Background:</title><p id="P9">Open-access opioid treatment programs (OTP) offer same-day access to methadone without an appointment and aim to minimize treatment barriers that often reduce admission and/or retention. We explored whether patients with benzodiazepine exposure at treatment entry would have similar 12-month retention compared to those without benzodiazepine exposure.</p></sec><sec id="S2"><title>Methods:</title><p id="P10">We conducted a retrospective cohort study of 2968 patients consecutively initiated on methadone between January 2015 and February 2017 at an open-access OTP. The sample was stratified into benzodiazepine-exposed and nonexposed groups based on intake urine toxicology. Group comparison of 12-month retention was conducted. Kaplan Meier analysis compared time to methadone treatment discontinuation between groups with a log-rank test. Multivariable Cox regression was performed to compare retention by baseline benzodiazepine exposure with adjustment for confounders.</p></sec><sec id="S3"><title>Results:</title><p id="P11">Overall, 31% of patients with benzodiazepine exposure (n=171) and 31% without exposure (n=2423) were retained at 12 months (p=0.95). Median treatment duration was 182 days (95% CI, 152&#8211;239) and 175 days (95% CI, 156&#8211;196) for patients with and without benzodiazepine exposure, respectively. Kaplan-Meier analysis showed no significant difference in treatment duration between groups (log-rank test p=0.73). Cox regression found no difference in treatment retention between groups (adjusted Hazard Ratio= 1.03, 95% CI, 0.91&#8211;1.16).</p></sec><sec id="S4"><title>Conclusions:</title><p id="P12">In this cohort of patients receiving methadone at an open-access OTP, benzodiazepine exposure at intake was not observed to impact 12-month treatment retention or duration. These findings support U.S. Food and Drug Administration (FDA) recommendations to not withhold medications for opioid use disorder from patients taking benzodiazepines.</p></sec></abstract><kwd-group><kwd>benzodiazepine</kwd><kwd>opioid use disorder</kwd><kwd>methadone</kwd><kwd>treatment retention</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front></article></pmc-articleset>